Full Press Release Details
NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update
Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led by Frazier
Healthcare Partners and Bain Capital Life Sciences, extending expected cash runway through 2026
topline results from ROSE2 Phase 2 clinical trial evaluating obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy; plan to present full data at NLA Scientific Sessions in June 2023
Initiated Phase 2 dose-finding study evaluating obicetrapib in Japanese patients; expect to report topline results in 2H 2023
Pivotal Phase 3 BROOKLN, BROADWAY and PREVAIL trials on-track
Naarden, the Netherlands and Miami, USA; March 31, 2023 NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or
NewAmsterdam or the Company ), a clinical-stage company focused on the research and development of transformative oral therapies for major cardiometabolic diseases, today announced its financial results for the full year ended
December 31, 2022 and provided a corporate update.
2022 was a transformative year for NewAmsterdam, and we are thrilled to have achieved
significant corporate and clinical milestones that have propelled our company forward. From securing a major pharmaceutical partner to support potential commercialization efforts in Europe, to going public through a successful deSPAC and concurrent
oversubscribed PIPE financing, we have fortified our position as a leader in the cardiometabolic space, said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam. Our positive topline data readout in the ROSE2 Phase 2 clinical
trial, the initiation of a Phase 2 dose-finding study in Japanese patients, and the advancement of our three pivotal Phase 3 BROOKLYN, BROADWAY and PREVAIL trials underscore our commitment to developing innovative treatments for patients worldwide.
With the capital we believe is needed to support our clinical operations through completion of these pivotal trials, we are confident in our ability to unlock the full potential of obicetrapib and deliver value to the millions of people in need of
an effective and convenient LDL-C lowering therapy.
Fourth Quarter and Recent Business Highlights:
Clinical Pipeline Updates
developing obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred low-density lipoprotein cholesterol
( LDL-C ) lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients. The Company is currently conducting three pivotal Phase 3
clinical trials of obicetrapib: BROOKLYN, evaluating the effect of obicetrapib on LDL-C levels in patients with heterozygous familial hypercholesterolemia ( HeFH ) as an adjunct to maximally
tolerated lipid-lowering therapy; BROADWAY, evaluating the effect of obicetrapib on top of maximally tolerated lipid-lowering therapy in patients with established atherosclerotic cardiovascular disease ( ASCVD ); and PREVAIL, a
cardiovascular outcomes trial in patients with a history of ASCVD with inadequately controlled LDL-C despite treatment with maximally tolerated lipid-modifying therapies.
Corporate Highlights
Upcoming Potential Milestones
NewAmsterdam expects to achieve the following upcoming milestones:
Full Year 2022 Financial Results
Based on its current operating and development plans, NewAmsterdam believes that its existing cash, cash equivalents and available-for-sale securities will fund operations through 2026, beyond the readout of its three ongoing Phase 3 trials, BROADWAY, BROOKLYN and PREVAIL.
NewAmsterdam Pharma (Nasdaq: NAMS) is
a clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated. NewAmsterdam is
investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximally-tolerated
statin therapy for high-risk cardiovascular disease ( CVD ) patients. Results from NewAmsterdam Pharma s ROSE Phase 2b trial (presented at AHA Scientific Sessions in 2021) included observations that patients receiving obicetrapib 10
mg experienced a median reduction in LDL-C of 51% versus baseline in patients on high-intensity statin therapy (vs. a 7% reduction in the placebo arm). In addition, topline results from NewAmsterdam
Pharma s ROSE2 trial evaluating the combination of 10 mg obicetrapib and 10 mg ezetimibe demonstrated a median reduction in LDL-C levels of 59% versus baseline in patients on high-intensity statin therapy
(vs. a 6% reduction in the placebo arm). Based in the Netherlands, NewAmsterdam recently completed a business combination with FLAC, a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners. Proceeds from this
transaction were approximately $328 million, prior to deducting transaction expenses. In June 2022, NewAmsterdam Pharma entered into an exclusive licensing agreement with the Menarini Group for the commercialization of obicetrapib in Europe,
while retaining all rights to commercialize obicetrapib, if approved, in the rest of the world, as well as rights to develop certain forms of obicetrapib for other diseases such as Alzheimer s disease. For more information, please visit:
Forward-Looking Statements
Certain statements included in this document that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the
United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as believe, may, will, estimate, continue,
anticipate, intend, expect, should, would, plan, predict, potential, seem, seek, future, outlook and
similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the Company s business and strategic
plans, cash runway, the therapeutic and curative potential of the Company s product candidate, the Company s clinical trials and the timing for enrolling patients, the timing and forums for announcing data and the achievement and timing of
regulatory approvals. These statements are based on various assumptions, whether or not identified in this document, and on the current expectations of the Company s management and are not predictions of actual performance. These
forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and
circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties,
including changes in domestic and foreign business, market, financial, political, and legal conditions; risks relating to the uncertainty of the projected financial information with respect to the Company; risks related to the approval of the
Company s product candidate and the timing of expected regulatory and business milestones;
ability to negotiate definitive contractual arrangements with potential customers; the impact of competitive product candidates; ability to obtain sufficient supply of materials; the impact of COVID-19; global economic and political conditions, including the Russia-Ukraine conflict; the effects of competition on the Company s future business; and those factors described in the Company s public
filings with the U.S. Securities and Exchange Commission. Additional risks related to the Company s business include, but are not limited to: uncertainty regarding outcomes of the Company s ongoing clinical trials, particularly as they
relate to regulatory review and potential approval for its product candidate; risks associated with the Company s efforts to commercialize a product candidate; the Company s ability to negotiate and enter into definitive agreements on
favorable terms, if at all; the impact of competing product candidates on the Company s business; intellectual property related claims; the Company s ability to attract and retain qualified personnel; ability to continue to source the raw
materials for its product candidate. If any of these risks materialize or the Company s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional
risks that the Company does not presently know or that the Company currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements
reflect the Company s expectations, plans, or forecasts of future events and views as of the date of this document and are qualified in their entirety by reference to the cautionary statements herein. The Company anticipates that subsequent
events and developments may cause the Company s assessments to change. These forward-looking statements should not be relied upon as representing the Company s assessment as of any date subsequent to the date of this communication.
Accordingly, undue reliance should not be placed upon the forward-looking statements. Neither the Company nor any of its affiliates undertakes any obligation to update these forward-looking statements, except as may be required by law.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
| As at December 31, | ||||||||||||
| Note | 2022 | 2021 | ||||||||||
| (In thousands of Euro) | ||||||||||||
| Assets | ||||||||||||
| Non-current assets | ||||||||||||
| Intangible assets | 15 | 83,160 | ||||||||||
| Property, plant and equipment | 13 | 144 | 190 | |||||||||
| Loan receivable | 14 | 718 | ||||||||||
| Long term prepaid expenses | 5 | 146 | ||||||||||
| Total non-current assets | 83,450 | 908 | ||||||||||
| Current assets | ||||||||||||
| Prepayments and other receivables | 10 | 9,611 | 5,782 | |||||||||
| Cash | 18 | 438,522 | 53,092 | |||||||||
| Total current assets | 448,133 | 58,874 | ||||||||||
| Total assets | 531,583 | 59,782 | ||||||||||
| Equity and liabilities | ||||||||||||
| Equity | ||||||||||||
| Share capital | 19 | 599,191 | 83,876 | |||||||||
| Other reserves | 20 | 4,691 | 591 | |||||||||
| Accumulated loss | (119,361 | ) | (34,676 | ) | ||||||||
| Total equity | 484,521 | 49,791 | ||||||||||
| Non-current liabilities | ||||||||||||
| Deferred revenue | 5 | 4,492 | ||||||||||
| Lease liability | 22 | 56 | 111 | |||||||||
| Derivative earnout liability | 17 | 7,053 | ||||||||||
| Total non-current liabilities | 11,601 | 111 | ||||||||||
| Current liabilities | ||||||||||||
| Trade and other payables | 11 | 18,503 | 9,827 | |||||||||
| Deferred revenue | 5 | 13,008 | ||||||||||
| Lease liability | 22 | 62 | 53 | |||||||||
| Derivative warrant liabilities | 17 | 3,888 | ||||||||||
| Total current liabilities | 35,461 | 9,880 | ||||||||||
| Total equity and liabilities | 531,583 | 59,782 |
CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND COMPREHENSIVE LOSS
| For the year ended December 31, | ||||||||||||||||
| Note | 2022 | 2021 | 2020 | |||||||||||||
| (In thousands of Euro, except per share amounts) | ||||||||||||||||
| Revenue | 5 | 97,500 | ||||||||||||||
| Research and development expenses | 6 | (82,230 | ) | (25,032 | ) | (4,045 | ) | |||||||||
| Selling, general and administrative expenses | 7 | (22,230 | ) | (4,803 | ) | (1,384 | ) | |||||||||
| Share listing expense | 9 | (60,600 | ) | |||||||||||||
| Total operating expenses | (165,060 | ) | (29,835 | ) | (5,429 | ) | ||||||||||
| Operating loss | (67,560 | ) | (29,835 | ) | (5,429 | ) | ||||||||||
| Finance income | 14 | 11 | 9 | |||||||||||||
| Finance expense | 22 | (271 | ) | (216 | ) | (344 | ) | |||||||||
| Fair value change earnout and warrants | 17 | (976 | ) | |||||||||||||
| Foreign exchange gains/(losses) | 16 | (9,256 | ) | 1,443 | 24 | |||||||||||
| Loss before tax | (78,052 | ) | (28,599 | ) | (5,749 | ) | ||||||||||
| Income tax expense | 12 | |||||||||||||||
| Loss for the year | (78,052 | ) | (28,599 | ) | (5,749 | ) | ||||||||||
| Other comprehensive loss, net of tax | ||||||||||||||||
| Total comprehensive loss for the year, net of tax | (78,052 | ) | (28,599 | ) | (5,749 | ) | ||||||||||
| Net loss per share (in Euro) | 21 | |||||||||||||||
| Basic and diluted | (0.96 | ) | (1.19 | ) | (0.54 | ) |
Spectrum Science on behalf of NewAmsterdam
Stern Investor Relations on behalf of NewAmsterdam